Findings highlight the clinical and radiographic burden of D2M-axSpA and emphasize the need for optimized treatment strategies, particularly in patients with comorbidities, a history of anterior uveitis or peripheral arthritis, and those with a smoking history.
Cinakli et al. (Wed,) studied this question.